Dr Reddys Laboratories

The company's board also recommended a final dividend of Rs 30 per equity share of face value of Rs. 5 each for the financial year 2021-22.

It is a first-of-its-kind integrated and cashless digital health solution in India, the statement said

Apollo Hospitals and Dr Reddy's Laboratories on Monday said they are collaborating to initiate a COVID-19 vaccination programme in the country with Sputnik V. The first phase of the programme will kick off with vaccinations in Hyderabad on Monday and in Visakhapatnam on Tuesday (May 18) at Apollo facilities. The vaccinations would follow the SOPs as recommended by the government including registration on CoWIN. Apollo Hospitals' Joint Managing Director Sangita Reddy said the healthcare major would receive 10 lakh doses of the COVID-19 vaccine over a period of one month. "Delighted to share @HospitalsApollo has Ptnr with @drreddys 2 admin #SputnikV the 1st foreign-made #vaccine to be used in #India to all DRL staff. Additionally, we will be receiving 1 Mn doses (over 1 mth period ) 4 our public #vaccinationdrive as #IndiaFightsCOVID19," she tweeted. For the pilot programme, Apollo would receive the Sputnik V vaccines from the first batch of 1.5 lakh doses imported by Dr Reddy's s

Dr Reddy's Laboratories on Friday reported 29 per cent decline in consolidated net profit at Rs 557 crore for the fourth quarter ended March 31, 2021. The Hyderabad-based drug major had posted a net profit of Rs 781 crore in January-March period of 2019-20. Net sales however rose to Rs 4,608 crore in the quarter under review as compared with Rs 4,336.1 crore in the fourth quarter of 2019-20, Dr Reddy's Laboratories said in a regulatory filing. For 2020-21 fiscal year, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20. Net sales increased to Rs 18,420 crore during the last fiscal year as compared with Rs 16,357 crore in 2019-20. "In FY 21, we continued to grow across all our businesses, enhance productivity and strengthen our development pipeline," Dr Reddy's Laboratories Co-Chairman and MD G V Prasad said. The company is prioritising its efforts to launch Sputnik V vaccine across India while working on the development and ...

RDIF CEO Kirill Dmitriev in a virtual press conference recently said he expected over 50 million doses of SputnikV vaccine to be manufactured in India by this summer

Russian Covid-19 vaccine granted restricted emergency-use authorisation in India

The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study

Containers with logos of Dr Reddy's and Sputnik V being unloaded from a small truck was seen

Such businesses outperform non-family firms by 3% in first six months of CY20, says Credit Suisse report

Steady improvement in the US and India market growth keeps analysts positive

BS ReporterHyderabad, 10 August: In a set back to Dr Reddy's Laboratories Limited, German regulatory authority has not renewed the GMP(good manufacturing practices)compliance certificate in respect of the company's formulations manufacturing Unit 2 plant in Bachupally in Hyderabad.In the absence of compliance certificate, Dr Reddy's can not export drug products to European Union from this facility. The German regulator's decision came after a recent inspection of the facility by its team."betapharm Arzneimittel GmbH, Germany(Dr Reddy's wholly owned subsidiary) received a communication from the Regulatory Authority of Germany last night, that the GMP compliance certificate in respect of the company's formulations manufacturing unit 2 in Bachupally is not renewed consequent to the recent inspection of the plant. Pending revocation of the non-compliance notification, the plant will not be able to make any further despatches to the European Union until the next inspection, to be ...

Recently, USFDA had issued a Form-483 with two observations after inspecting co's unit

The stock slipped 5% to Rs 2,602 on BSE in intra-day trade on back of heavy volumes.

The stock has fallen to its 52-week low of Rs 2,751, down 3.5% on BSE in early morning trade.

The stock dipped 5% to Rs 3,305 on the BSE.

The stock dipped 4% to Rs 3,465, extending its past two days 2% decline on the BSE.